The updated ZEISS femtosecond laser offers U.S. refractive surgeons faster treatment, greater flexibility and significant workflow improvements.
DUBLIN, California. and JENA, Germany, January 11, 2024 /PRNewswire/ — Carl Zeiss Meditec AG — ZEISS Medical Technology today announced that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® professional software from ZEISS to surgically treat myopia, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS comes to the US market at a time when more than 8 million eyes have been processed with SMILE worldwide, reflecting the global dynamics of the technology, driven by strong adoption in Asia And Europe.
“The growing global adoption of ZEISS SMILE represents the positive impact that the small incision lenticule extraction procedure continues to have on patient quality of life,” said Andrew Chang, Head of Global Sales of ZEISS Medical Technology. “With the availability of the ZEISS SMILE pro software module in the US market, surgeons can now offer the latest refractive technology to help them grow their business and deliver excellent patient outcomes.
“ZEISS continues to stand out in the US market with the availability of the VISUMAX 800 with ZEISS SMILE pro software, providing the latest digital technology from the company’s legacy of innovation to meet the evolving needs of refractive surgeons” , said Euan S. Thomson, Ph.D., President of the Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. “Part of the ZEISS medical ecosystem, this next-generation femtosecond laser system creates data-driven insights to help surgeons manage better treatment pathways for patients while meeting each surgeon’s unique practice requirements for greater workflow efficiency and performance.
The VISUMAX® 800 with SMILE® ZEISS Pro software enables faster processing, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also offers greater flexibility to the surgeon and patient, with a reduced footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise.
With the availability of VISUMAX® 800 with SMILE® pro from ZEISS in the United States, surgeons can use a number of workflow enhancements, including: the CentraLign® Centering Assist, a computer-controlled feature for easy centering; the OcuLign® cyclotorsion adjustment to help counteract cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling greater control during each surgical procedure.
With these workflow improvements along with greater flexibility and faster processing, the VISUMAX® 800 with SMILE® ZEISS Pro Software Provides Substantial Market Opportunities for U.S. Surgeons. “The VISUMAX 800 is a practice building tool and allows surgeons to differentiate their practice from their local competitors,” said Luc RebenitschMD, at ClearSight LASIK and 43Vision, in Oklahoma City, OKUNITED STATES.
For more information on VISUMAX® 800 with SMILE® ZEISS pro software, visit www.zeiss.com/us/visumax-800.
* Data recorded, myopia with optical zone 6.5 mm.
Not all products, services or offerings are approved or offered in all markets and approved labeling and instructions may vary by country. For country-specific product information, visit the respective country’s website. Product specifications are subject to changes in design and scope of delivery due to continuous technical development.
Contact for investors:
Sébastien Frericks
Group Finance and Investor Relations Manager
Carl Zeiss Meditec AG
Telephone: +49 3641 220 116
Email: investors.meditec@zeiss.com
Press contact:
Frank Smith
Head of Global Ophthalmic Device Communications
Carl Zeiss Meditec Inc.
Telephone: +49 3641 220 331
Email: press.med@zeiss.com
Brief profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), listed on the MDAX and TecDAX of the German Stock Exchange, is one of the world’s leading medical technology companies. The company provides innovative technologies and application-oriented solutions designed to help physicians improve the quality of life of their patients. The company offers comprehensive solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated a turnover of €2,089.3 million during the 2022/23 financial year (as of September 30).
The Group’s head office is located in Jena, Germanyand it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the UNITED STATES, Japan, Spain And France. The Application and Research Center (CARIn) of Bangalore, India and the Carl Zeiss Innovation Center for Research and Development at Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of the shares of Carl Zeiss Meditec AG are free float. The rest approx. 59 percent is owned by Carl Zeiss AG, one of the world’s leading groups in the optics and optoelectronics sectors.
For more information, visit: www.zeiss.com/med
SOURCE Carl Zeiss Meditec AG
